Liminatus Pharma (LIMN) Debt Ratio (2024 - 2026)

Liminatus Pharma (LIMN) posted Debt Ratio of 0.52 for Q1 2026, down 81.62% sequentially from 2.81 in Q4 2025.

Liminatus Pharma (LIMN) Debt Ratio (2024 - 2026) Analysis & Trends

Liminatus Pharma has reported Debt Ratio for 3 years, with the latest figure at 0.52 in Q1 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.52 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.52 (changed N/A YoY) and the FY2025 annual result came in at 2.81, down 23.82% from the prior year.
Debt Ratio declined to 0.52 in Q1 2026 per LIMN's latest filing, from 2.81 in the prior quarter.
Over five years, Debt Ratio peaked at 3.69 in Q4 2024 and troughed at 0.52 in Q1 2026.
A 3-year average of 1.77 and a median of 1.07 in 2025 frame the typical range for Debt Ratio.
The widest YoY moves for Debt Ratio: up 23.82% in 2025, down 23.82% in 2025.
Over 3 years, Debt Ratio stood at 3.69 in 2024, then slipped by 23.82% to 2.81 in 2025, then plunged by 81.62% to 0.52 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.52, 2.81, and 1.07 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.71 Bn	131.86 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.55 Bn	78.55 Bn	3.93 Bn	0.05
3	Argenx Se	65.26 Bn	60.07 Bn	1.37 Bn	-
4	Moderna	59.81 Bn	54.67 Bn	52.00 Mn	0.05
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.87 Bn	28.56 Bn	992.69 Mn	-
7	BioNTech SE	28.13 Bn	9.74 Bn	668.28 Mn	0.03
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.31 Bn	26.47 Bn	-	0.47
10	Liminatus Pharma	257.00 Mn	257.00 Mn	-	0.42

Download Data